natgillin/translations-raw huggingface dataset:
The artemisinin compound for use according to claim 1 or 2, wherein the compound is administered to the patient in a therapeutically effective amount, preferably by systemic or local administration. 
Spoj artemizinina namijenjen upotrebi u skladu sa zahtjevom 1 ili 2, naznačen time što se spoj primjenjuje na pacijentu u terapijski djelotvornoj količini za liječenje hipoinzulinemije, po mogućnosti sistemnom ili lokalnom primjenom.
The use according to any of the preceding claims, wherein the nucleic acid molecule is a nucleic acid expression construct, which comprises regulatory sequences being operatively linked with the nucleic acid sequence coding for the plant pentose transporter, and/or wherein the nucleic acid expression construct further comprises 5' and/or 3' recognition sequences and/or selection markers. 
Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je molekula nukleinske kiseline konstrukt za eksprimiranje nukleinske kiseline, koji sadrži regulacijske sljedove koji su operativno povezani s nukleinskokiselinskim slijedom koji kodira biljni transporter pentoza, i/ii gdje konstrukt za eksprimiranje nukleinske kiseline dodatno sadrži sljedove za prepoznavanje 5' i/ili 3? i/ili selekcijske biljege.
Use of Modulators to Affect Peptides of the Invention 
Datum podnošenja europske prijave patenta:
shaping the first rubber mixture by converting it to a rubber web; 
oblikovanje prve smjese kaučuka (2) njenim pretvaranjem u ploču od kaučuka (5);
The composition of claim 27, the kit of claim 28, or the use of any one of claims 35 to 39, wherein the second pharmaceutical agent is a monoclonal antibody. 
Sastav prema pateninom zahtjevu 26, naznačen time, da je drugi farmaceutski agens monoklonalno antitijelo.
A pharmaceutical composition comprising an antibiotic selected from antibiotic 107891, antibiotic 107891 Factor A1, antibiotic 107891 Factor A2, and a mixture of said Factors in any proportion or a pharmaceutically acceptable salt thereof with an acid. 
Farmaceutski sastav, naznačen time, da sadrži antibiotik odabran iz spojeva prema patentnom zahtjevu 1 ili njihovu farmaceutski prihvatljivu sol s kiselinom.
The vector of claim 4 wherein the pathogen specific antigen is derived from a human immunodeficiency virus, simian immunodeficiency virus, or Mycobacterium tuberculosis. 
Vektor prema patentnom zahtjevu 4, naznačen time, da je patološki specifičan antigen izveden iz virusa humane imunodeficijencije, simian virusa imunodeficijencije ii Mycobacterium tuberculosis.
is selected from methyl, ethyl, propyl or butyl (substituted by one or two groups selected from hydroxyl, phenyl and pyridinyl), cyclopentyl, hydroxycyclopentyl, and oxidotetrahydrothiophenyl, dioxidotetrahydrothiophenyl, tetrahydrofuranyl or oxotetrahydrofuranyl; or a pharmaceutically acceptable salt thereof. 
R* je odabran od metila, etila, propila ili butila (supstituiran s jednom ili dvije skupine koje su odabrane od hidroksila, fenila i piridinila), ciklopentila, hidroksiciklopentila, 1 oksidotetrahidrotiofenila, dioksidotetrahidrotiofenila, tetrahidrofuranila ili oksotetrahidrofuranila; ili njegova farmaceutski prihvatljiva sol.
WO 94/08567 0.03% by weight of polysorbate is applied in order to increase the ratio of product fraction. 
WO 94/08567 primjenjuje se 0,03% (težinski) polisorbata da bi se povećao udio frakcije produkta.
Use of a paint composition comprising a component A, being a basic binder and a component B, being an isocyanate prepolymer, wherein the isocyanate prepolymer has an NCO weight percentage of less than or equal to 16 wt.%, and wherein component A has been selected from the group consisting of hydroxyacrylate, polyaspartic ester, polyester polyol, epoxy, silicone epoxide, and one or more combinations hereof and wherein the index, being the ratio between reactive groups of component B and the reactive groups of component A, ranges between 1.5 and 3.0 as a paint or top coat having a thickness of maximally 150 µm and the layer has a loss of gloss ranging from 0 to 10 measured according to ISO11507:1997 after 1000 hours of irradiation with UV-A light. 
Uporaba sastava boje koji sadrži komponentu A, kao osnovno vezivo te komponentu B, kao prepolimer izocijanata, pri čemu prepolimer izocijanata ima NCO (DUK, dušik, ugljik, kisik) postotak težine niži ili jednak 16 wt.%, te pri čemu je komponenta A odabrana iz skupine koju čine hidroksiakrilat, poliaspartični ester, poliester poliol, epoksi, epoksid silikon, i jedna ili više kombinacija navedenih pri čemu indeks, omjer između reaktivnih grupa komponenti B 1 reaktivnih grupa komponenti A, iznosi između 1.5 1 3.0, te naznačen time što debljina sloja iznosi maksimalno 150 m um te sloj ima gubitak sjaja u opsegu od 0 do 10 mjereno sukladno ISO11507:1997 nakon 1000 sati iradijacije UV-A svjetlom.
In one embodiment, the persisting population of genetically engineered T cells comprises a memory T cell. In one embodiment, the persisting population of genetically engineered T cells persists in the human for at least three months after administration. 
T stanica za upotrebu prema patentnom zahtjevu 10, naznačena time što primijenjena genetički konstruirana T stanica proizvodi potomstvo T stanica u čovjeku koje sadrži memorijsku T stanicu.
A device as claimed in any one of the claims 4 to 6, characterized in that the cap comprises a sleeve portion that bounds the grip surface portion and surrounds the tube at least over part of a length and includes a top portion that extends over the open end of the tube, where the sleeve portion and top portion can be manually detached relative to each other for releasing the barrier layer. 
Naprava u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što poklopac ima tuljasti dio koji se nalazi uz dio s površinom za držanje i okružuje cijev u najmanju ruku na dijelu duljine, te što poklopac uključuje gornji dio koji se pruža preko otvorenog kraja cijevi, gdje se tuljasti dio i gornji dio mogu ručno odvojiti jedan od drugog radi skidanja graničnog sloja.
A compound of the formula: 
Spoj s formulom: [image]
The composition of claim 3 wherein the acid functional acrylate copolymer has a number average molecular weight under 10,000, preferably between 2,000 and 6,000. 
Sastav prema zahtjevu 3, naznačen time da kiselo-funkcionalni akrilat-kopolimer ima brojčano srednju molekularnu težinu ispod 10.000, u prednosti između 2.000 i 6.000.
compacting the lubricated blend to ribbons of density in a range of 1.1 to 1.2 g/ cm3 and sizing the compacted ribbons using a roller compactor, and 
sabijanje ovlažene smjese u trake gustoće u opsegu od 1.1 do 1.2 g/cc i formiranje do dobijene veličine sabijenih traka uporabom valjka kompaktora, i gdje postupak vlažne granulacije obuhvaća:
A combination according to any of the preceding claim for use in potentiating the analgesic effect of opioids and/or for decreasing the dependency induced by opioids. 
Sastav prema bilo kojem od prethodnih zahtjeva za uporabu u potenciranju analgetičkog efekta opioida ili opijata iili za smanjenje njima uzrokovane ovisnosti.
The compound or salt for use according to claims 1 or 2, wherein X is N. 
Farmaceutski sastav prema zahtjevu 1 ili 2, pri čemu X je N.
According to a further feature of this aspect of the invention there is provided a chromenone derivative of the Formula I, or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in the treatment of cancer of the bile duct, bone, bladder, head and neck, kidney, liver, gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix and vulva, and of leukaemias (including ALL and CML), multiple myeloma and lymphomas. 
Derivat kromenona prema formuli I, ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 12, naznačen time da je za uporabu kod liječenja raka žučovoda, kosti, mjehura, glave i vrata, bubrega, jetre, probavnog tkiva, jednjaka, jajnika, gušterače, kože, testisa, štitnjače, uterusa, grlića maternice i vulve, te leukemija, multiplog mijeloma i limfoma.
the synergism is supra-additive). 
sinergija je iznad aditivne).
The compound or composition for use according to claim 1, wherein the disease or disorder is fallopian tube cancer. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je karcinom jajnika.
An object of this invention more specifically relates to the use of an AAV vector comprising a gene of interest (e.g., encoding a therapeutic or diagnostic product) for the manufacture of a medicament for delivering the gene to cells in the central nervous system, particularly motor neurons or glial cells, by peripheral administration of said AAV vector to said subject. 
HR P20140643 T1 PATENTNI ZAHTJEVI AAV vektor koji sadrži gen od interesa za uporabu u metodi za dostavu navedenog gena od interesa motoričkim neuronima ili glija stanicama intraperitonealnim (i.p.), intramuskularnim (i.m.) ili intravenskim (i.v.) injiciranjem, poželjno intravenskim injiciranjem, navedenog AAV vektora subjektu, pri čemu je navedeni AA V vektor:
a second pump (4) to receive the compressed LNG and to compress the LNG to a pressure of 200 to 300 bar (gauge pressure) to meet the pressure requirements for the high-pressure gas injection engine. 
drugu crpku (4) konfiguriranu da dodatno stlačuje LNG na visoki pritisak i da dobavlja dodatno komprimirani LNG prema visokotlačnom plinskom injekcijskom motoru;
The method according to claim 13, wherein the component d) is octanol. 
Metoda u skladu sa patentnim zahtjevom 13, naznačena time da je komponenta označena slovom d) oktanol.
Microcapsules comprising a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact to a liver cell stimulating amount of erythropoietin. 
Mikrokapsule naznačene time da se sastoje od ovojnice kapsule koja inkapsulira suspenziju terapeutski učinkovite količine stanica jetre u fizičkom kontaktu sa količinom eritropoietina koja stimulira stanicu jetre.
A sustained release aminopyridine composition for use in a method of treating multiple sclerosis, wherein said composition is administered twice daily in a dose of 10 milligrams or less of aminopyridine. 
Sastav aminopiridina s odgođenim oslobađanjem za upotrebu u postupku tretiranja multiple skleroze, naznačen time da je spomenuti sastav primijenjen dvaput dnevno u dozi od 10 miligrama ili manje aminopiridina.
The compound of claim 1, wherein the alkyd polymer has a mean molecular weight of more than 4000. 
Spoj prema zahtjevu 1 ili 2, čija je značajka to što alkidni polimer ima prosječnu molekulsku masu veću od 4000.
The vertically expanding bag (1900) of claim 8, further comprising doors that cover the cavities when the four wheels (1980) are not in use. 
Torba koja se može izduljiti po visini (1900) prema zahtjevu 8, koja dalje obuhvaća poklopce koji zatvaraju šupljine kad se kotačići (1980) ne koriste.
Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by 1-3 substituents, independently selected from the group consisting of a halogen atom, a lower alkyl group optionally substituted by a lower alkoxy group, a lower alkoxy group optionally substituted by a halogen atom or a lower alkoxy group, a cycloalkyl group, a cycloalkoxy group, and an oxo group; 
a je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C1-6 alkilnom skupinom, halogen-C1-6 alkilnom skupinom, C1-6 alkoksi skupinom, halogen-C1-6 alkoksi skupinom, metilendioksi skupinom, etilenoksi skupinom ili mono- ili di-C1-6 alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, C1-6 alkilnom skupinom ili C1-6 alkoksi skupinom.
To support the shell prior to insertion of the cup body it is advantageous that the apparatus comprise a receiving member with at least a skirt portion and an upper flange used for holding the shell. 
Da bi se ljuska smjestila prije umetanja tijela čaše, poželjno je da uređaj ima element za prihvaćanje koji ima najmanje jedan predio s rubom i gornju prirubnicu koja se koristi za držanje ljuske.
The floating lake system of claim 1, wherein the walls comprise a permeable material that allows for water from the water body in which the floating lake is installed to pass through the walls at a predetermined permeation rate. 
Sustav plutajućeg jezera (1) prema zahtjevu 14, naznačen time što stjenke (3) sadrže propusni materijal koji omogućava da voda iz vodenog tijela u kojem je plutajuće jezero instalirano prolazi kroz zidove (3) uz unaprijed određenu brzinu propusnosti.
The macrocapsule 52 was formed from a 15 mm long piece of 4 mil (0.10 mm) thick aluminum foil, which was crimped to form a 12 mm long capsule. 
Makrokapsula 52 je formirana sa 15 mm dugim komadom aluminijske folije debele 0.10 mm, koja je naborana tako da se formira 12 mm duga kapsula.
or alternatively, the steps of;. 
ili alternativno koracima:
A highly concentrated, stable pharmaceutical anti-HER2 antibody formulation according to claim 1 or claim 2, wherein the anti-HER2 antibody concentration is 100 to 150 mg/ml, 120 ± 18 mg/ml, about 110 mg/ml, about 120 mg/ml, or about 130 mg/ml, respectively. 
Visoko koncentrirana, stabilna farmaceutska formulacija protutijela anti-HER2 prema zahtjevu 1 ili zahtjevu 2, naznačena time, da koncentracija protutijela anti-HER2 je od 100 do 150 mg/ml ili oko 120 +18 mg/ml ili oko 110 mg/ml ili oko 120 mg/ml ili oko 130 mg/ml.
The application device according to claim 1, characterized in that said forming unit (30) comprises guiding means (34) for said primary container (20) comprising at least one wall suitable for at least partially externally enfolding said primary container (20). 
Uređaj za primjenu u skladu s patentnim zahtjevom 1, naznačen time što navedena jedinica za oblikovanje (30) ima element za vođenje (34) za navedeni primarni spremnik (20), koji ima najmanje jednu stijenku pogodnu za u najmanju ruku djelomično nabiranje navedenog primarnog spremnika (20) izvana.
A treated RNA composition comprising in vitro -synthesized ssRNA or mRNA, wherein less than 0.01%, preferably less than 0.001%, further preferably less than 0.0002% of the of the mass of RNA in said treated RNA composition is double-stranded RNA (dsRNA) of a size greater than about 40 basepairs in length; wherein said treated RNA composition has been obtained by treating in vitro-synthesized ssRNA with a dsRNA-specific endoribonuclease III protein in a buffered aqueous solution comprising magnesium cations at a concentration of about 1-4 mM, and a salt providing an ionic strength equivalent to at least about 50 mM potassium acetate or potassium glutamate. 
Obrađeni sastav ribonukleinske kiseline (dalje u tekstu:RNA), koji sadrži in vitro sintetiziranu ssRNA ili mRNA, gdje je manje od 0,01%, poželjno manje od 0,001%, nadalje, poželjno manje od 0,0002% mase RNA u spomenutom tretiranom sastavu RNA dvolančana RNA (dsRNA) veličine veće od oko 40 duljina parova; pri čemu je navedeni obrađeni sastav ribonukleinske kiseline dobiven obradom ssRNA sintetiziranom in vitro s proteinom specifičnim za dsRNA endoribonukleaza III u puferiranoj vodenoj otopini koja sadrži katione magnezija u koncentraciji od oko 1-4 mM, te soli koja daje ionsku snagu ekvivalentnu barem oko 50 mM kalijevog acetata ili kalijevog glutamata.
cycle B is as defined in claim 1, wherein the depicted cycles are substituted with halogen, C1-4alkyl, or C1-4alkoxy; 
ciklički spoj B je kako je definirano u zahtjevu 1, pri čemu prikazani cikli su supstituirani sa halogenom, C1-4alkilom, ili C1-4alkoksi;
The method of claim 28, further comprising monitoring the subject for the observed adverse effect after the therapeutically effective amount of the composition is decreased, wherein if the adverse effect is no longer observed, the therapeutically effective amount of the composition is increased. 
dC ili dT, namijenjeni upotrebi u skladu s patentnim zahtjevom 20, naznačeni time što dodatno uključuju praćenje subjekta na opaženi štetni učinak nakon smanjivanja terapijski djelotvorne količine pripravke, gdje ako se štetni učinak više ne opaža, terapijski djelotvornu količinu pripravka se povećava.
Textile product containing bioceramic microparticles imbedded into the fibers thereof, provided to be used in human beings and animals, characterized in that the textile product contains bioceramic microparticles with high capacity of infrared irradiation which, in contact with the heat of the human body is capable of transmitting infrared radiation in the range of 3.0 µm to 14.8 µm, the infrared radiation inside this wavelength range being capable of regulating the blood microcirculation as a result of its high protection, wherein said bioceramic microparticles are provided with at least aluminum silicate, zinc oxide and barium magnesium carbonate. 
Tekstilni proizvod koji sadrži biokeramičke mikročestice ugrađene u vlakna‚ za upotrebu kod ljudi i životinja‚ naznačen time da tekstilni proizvod sadrži biokeramičke mikročestice s visokom sposobnošću infracrvenog zračenja koje‚ u kontaktu toplinom ljudskog tijela ima mogućnost prenošenja infracrvenog zračenja u dosegu od 3.0 µm do 14.8 µm, infracrveno zračenje unutar tih valnih duljina ima mogućnost reguliranja mikrocirkulacije krvi kao rezultat svoje visoke zaštite‚ pri čemu su navedene biokeramičke mikročestice opremljene barem aluminij silikatom‚ cink oksidom i barij magnezij karbonatom.
A compound of general formula (I): in which: 
Spoj opće formule (I):
Method of installing a rat trap according to one or more of claims 6, 7, 8, 9 or 10 in a sewer shaft having a well cover and one or more sewer pipe entrances, characterised in that the trap housing is positioned so that the killing means is able to operate right in front of a sewer pipe entrance, and in that the battery housing is mounted above the trap housing and below the well cover. 
Kanalizacijsko okno sa zamkom za štakore prema jednom ili više prethodnih zahtjeva 9-11, naznačeno time da zamka za štakore sadrži nosač pomoću kojeg kućište za bateriju može biti postavljeno u gornjem dijelu okna, tako da je izmjena baterije kao i nadzor zamke lako dostupan bez potrebe za uklanjanjem kućišta za zamku.
A compound for use as defined in claim 6 wherein the nervous system diseases are neurodegenerative disorders associated with cognitive deficits selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, fronto temporal dementia and Friedrich's ataxia. 
Spoj, namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što su bolesti živčanog sustava neurodegenerativni poremećaji, povezani s poremećajima kognitivnih funkcija koje se bira iz skupine koju čine Alzheimerova bolest, Parkinsonova bolest, Huntingtonova bolest, amiotrofna lateralna skleroza, fronto-temporalna demencija i Friedrichova ataksija.
The coated interior panel of claim 4, wherein said modified clay is one of a modified smectite clay, a modified hydrous sodium lithium magnesium silicate and mixtures thereof. 
Obložena ploča iz zahtjeva 8, naznačena time što je modificirana glina modificirana smektitna glina, modificirani vodeni natrijev litijev magnezijev silikat i njihove mješavine.
1994, 35, 3225-3226 as detailed in the experimental. 
1994., 35, 3225-3226, kako je prikazano u reakciji pokusa.
The shoe according to claim 1, wherein said sealing area is provided by a sealing layer which is pre-injected and onto which the sole is applied. 
Cipela u skladu s patentnim zahtjevom 6, naznačena time, da se na navedenoj površini za brtvljenje (A) nalazi sloj za brtvljenje (20) koji se prethodno ubrizgava i na koji se postavlja potplat.
The method according to claim 5, wherein the layer-1 information further includes at least one of an identifier of the PLP, a code rate of error correction coding of the PLP, a symbol mapping method of the PLP, the number of error correction coded blocks of the PLP, and a start symbol location on the multiplexed signal frame of the PLP. 
Postupak u skladu sa zahtjevom 5, naznačen time, što sloj-1 informacije uključuje nadalje najmanje jedan identifikator PLP, kodni omjer ispravljanja pogrešaka kodiranja PLP, postupak oblikovanja simbola PLP, broj ispravljanja pogrešaka kodiranih blokova PLP, i lokaciju početnog simbola na multipleksiranom okviru signala PLP.
Method according to one or more of claims 1 to 9, wherein the catalyst (N-cat) is selected from the group consisting of acetic acid, formic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, HCl, HBr, H2SO4, H3PO4, BCl3, BF3OEt2, MgCl2, MgBr2, AlCl3, ZnCl2, Cu(BF4)2, aluminosilicates, acidic ion exchange resins, carbon treated with HCl, H2SO4 or HNO3, and mixtures thereof. 
Postupak prema jednom ili više zahtjeva 1 do 9, naznačen time da katalizator (N-kat.) bude odabran iz skupine koja se sastoji iz octene kiseline, mravlje kiseline, trifluoroctene kiseline, metansulfonske kiseline, ptoluolsulfonske kiseline, HC1, HBr, H2SO4, H3PO4, BCI3, BF30Et2, MgC12, MgBr2, AICI3, ZnC12, Cu(BF4)2, alumino silikata, kiselih smola ionskih izmjenjivača, s ugljikom tretiranim HCI, H2SO4 ili HNO3 i njihovim mješavinama.
The composition for use of any of claims 1-6, wherein the composition is substantially devoid of antigens. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-3, pri čemu se sastav daje kao monoterapija.
when the upper SAO merging information indicates that the SAO parameters of the current block are determined according to SAO parameters of an upper block, determining the SAO parameters of the luma component of the current block to be identical to SAO parameters of a luma component of the upper block, and the SAO parameters of the chroma components of the current block to be identical to SAO parameters of chroma components of the upper block; 
kada lijeva informacija SAO spajanja označava da su parametri SAO trenutnog bloka određeni prema parametrima SAO lijevog bloka, određivanje parametara SAO komponenata luminancije trenutnog bloka kako bi bili identični parametrima SAO komponenata luminancije lijevog bloka, i parametri SAO komponenata krominancije trenutnog bloka kako bi bili identični parametrima SAO komponenata krominancije lijevog bloka;
In some implementations, the system also may include a first cable disposed through an aperture proximate a leading edge of each airfoil-shaped profile, to orient and balance the flexible wing(s); and a second cable disposed through an aperture proximate a gravitational center of mass of the airfoil-shaped profile for transferring torque to the machine. 
Sustav (10) za generiranje snage prema Zahtjevu 1, gdje sustav dalje sadrži drugi kabel (24) postavljen kroz otvor (36) najbliži centru mase aerodinamično oblikovanog profila (30) radi prenošenja momenta na stroj.
In another preferred embodiment, the said 2-aminoethanol additive has a chemical purity of more than 90 wt %, preferably more than 95 wt %, more preferably more than 99 wt % in respect to 2-aminoethanol. 
Uporaba prema zahtjevu 1 ili 2, naznačena time što 2-aminoetanol aditiv ima kemijsku čistoću više od 90 wt%, poželjno više od 95 wt%, poželjnije više od 99 wt% u odnosu na 2-aminoetanol.
The pharmaceutical or veterinary composition of claim 5 for use in the treatment or prevention of bacterial infections or disorders associated with bacterial infections in an animal. 
Farmaceutski ili veterinarski pripravak u skladu s patentnim zahtjevom 5, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bakterijskih infekcija ili poremećaja povezanih s bakterijskim infekcijama kod životinje.
In table 1, R1 is an unsubstituted pyrimidin-4-yl group or an unsubstituted pyridin-4-yl group, p, o and m represent 2, q represents 0. 
25 UTablici 1: RI je nesupstituirana pirimidin-4-ilna skupina ili nesupstituirana piridin-4-ilna skupina, p, 01 m znače 2, a q znači 0.
compressing bulk material in a chamber to form a bale of compressed bulk material; 
(a) komprimiranje rasutog (bulk) materijala u komori radi formiranja bale rasutog (bulk) materijala;
formulating the purified RNA as a pharmaceutical composition. 
(b) formuliranja pročišćene RNA kao farmaceutski pripravak.